非编码RNA在结直肠癌抗表皮生长因子受体治疗耐药中作用机制的研究进展  

Research advances in mechanism of noncoding RNAs in the resistance to anti-epidermal growth factor receptor therapy in colorectal cancer

作　　者：张筱倩 王金贵 文龙 陈善稳 张峻岭[1] 汪欣[1] Zhang Xiaoqian;Wang Jingui;Wen Long;Chen Shanwen;Zhang Junling;Wang Xin(Department of General Surgery,Peking University First Hospital,Beijing 100034,China;Department of Colorectal Surgery,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,No.17,Panjiayuan Nanli,Chaoyang District,Beijing 100021,China)

机构地区：[1]北京大学第一医院普通外科,100034 [2]国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院结直肠外科,100021

出　　处：《中华实验外科杂志》2020年第9期1775-1781,共7页Chinese Journal of Experimental Surgery

基　　金：深圳市三名工程。

摘　　要：结直肠癌(CRC)在世界范围内的发病率和死亡率分别位于恶性肿瘤的第三位和第二位。而抗表皮生长因子受体(EGFR)靶向药物(西妥昔单抗和帕尼单抗等)的应用,仅可以改善部分RAS原癌基因(RAS)野生型/鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)野生型CRC患者的预后。并且几乎所有开始对抗EGFR治疗敏感的CRC患者,也会在用药后的3~12个月内发展为继发性耐药。非编码RNA(ncRNA)主要包括微小RNA(miRNA)和长链非编码RNA(lncRNA)。既往研究表明,ncRNA可影响多种生物学进程,参与肿瘤的发生发展,并与多种药物的耐药密切相关。除此之外,研究结果显示ncRNA在对抗EGFR治疗耐药的CRC细胞中和CRC患者体内存在表达异常的现象。本文将针对miRNA和lncRNA在CRC抗EGFR治疗耐药中的作用机制进行综述,并探讨miRNA的表达量在预测CRC患者对抗EGFR治疗敏感性中的潜在作用。World widely,colorectal cancer(CRC)is the third most frequently occurring cancer and the second leading cause of cancer-related mortality.Epidermal growth factor receptor(EGFR)-targeting agents,such as Cetuximab and Panitumumab,could only improve the prognosis of some patients with RAS-wild-type/V-Raf Murine Sarcoma Viral Oncogene Homolog B1(BRAF)-wild-type CRC.But nearly all CRC patients who are sensitive to anti-EGFR therapy will also develop acquired resistance within 3-12 months of treatment.Noncoding RNAs(ncRNAs)mainly includes microRNAs(miRNAs)and long noncoding RNAs(lncRNAs).Previous studies have shown that ncRNAs could affect several biological processes,involve in the initiation and progression of tumors,and induce drug resistance.In addition,ncRNAs were found to be abnormally expressed in CRC cells and CRC patients with resistance to EGFR-targeting agents.This article reviews the mechanism of miRNAs and lncRNAs in the resistance to anti-EGFR therapy in CRC,and explores the potential role of miRNAs in predicting the sensitivity of anti-EGFR therapy in CRC patients.

关 键 词：非编码RNA 结直肠癌 表皮生长因子受体 耐药 

分 类 号：R735.34[医药卫生—肿瘤]